A Open-label, Prospective, Phase 1b Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer
Status: Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Rivoceranib (Primary) ; Carboplatin; Docetaxel
- Indications Advanced breast cancer; Early breast cancer
- Focus Therapeutic Use
- Acronyms LANCET
- 03 Feb 2018 Planned number of patients changed from 60 to 40.
- 03 Feb 2018 Planned primary completion date changed from 30 Aug 2019 to 30 Dec 2019.
- 03 Feb 2018 Planned initiation date changed from 2 Jan 2018 to 2 Apr 2018.